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ABSTRACT
A prior screening programme carried out using MTT assay by our group identified 
a series of novel benzimidazole derivatives, among which Methyl 2-(5-fluoro-2-
hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) showed highest 
anticancer efficacy compared to that of chemotherapeutic agent, cisplatin. In the 
present study, we found that MBIC inhibited cell viability in different hepatocellular 
carcinoma (HCC) cell lines without exerting significant cytotoxic effects on normal 
liver cells. Annexin V-FITC/PI flow cytometry analysis and Western blotting results 
indicated that MBIC can induce apoptosis in HCC cells, which was found to be mediated 
through mitochondria associated proteins ultimately leading to the activation of 
caspase-3. The exposure to MBIC also resulted in remarkable impairment of HCC cell 
migration and invasion. In addition, treatment with MBIC led to a rapid generation 
of reactive oxygen species (ROS) and substantial activation of c-Jun-N-terminal 
kinase (JNK). The depletion of ROS by N-Acetyl cysteine (NAC) partially blocked 
MBIC-induced apoptosis and JNK activation in HCC cells. Finally, MBIC significantly 
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inhibited tumor growth at a dose of 25 mg/kg in an orthotopic HCC mouse model. 
Taken together, these results demonstrate that MBIC may inhibit cell proliferation 
via ROS-mediated activation of the JNK signaling cascade in HCC cells.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most 
common and lethal cancers in the world, especially in 
men, and it is the second leading cause of cancer death 
in developing countries [1]. The majority of patients 
with HCC are diagnosed at an intermediate or advanced 
stage [2]. For patients with advanced HCC, systemic 
chemotherapy with small kinase inhibitors or cytotoxic 
agents provides marginal benefit; for example, sorafenib, 
an oral multi-tyrosine kinase inhibitor, is a standard of care 
for these patients, but the median overall survival for the 
patients treated with it is only around three months longer 
than for patients treated with placebo [3, 4]. Furthermore, 
HCC patients with multiple lung metastases have a poor 
prognosis with no efficacious treatment being identified 
till now [5]. Therefore, it is imperative to develop novel 
pharmacological agents for the treatment of HCC. 
Reactive oxygen species (ROS) play an essential 
role in cellular proliferation, differentiation, and apoptosis. 
In cancer therapy, majority of chemotherapeutics and 
radiotherapeutics destroy cancer cells by generating 
substantial quantity of ROS [6, 7]. The imbalance between 
the levels of oxidizing and reducing equivalents generates 
a high concentration of ROS that may lead to cell death 
[8]. ROS may act as intracellular messengers or alter the 
protein structure and function by oxidizing critical amino 
acid residues [9]. Several prior studies have described that 
ROS can mediate the sustained activation of the mitogen-
activated protein kinases (MAPK) pathways, which play 
a critical role in various physiological processes [10]. 
In human cells, the MAPK pathways consist of three 
different protein kinases including the extracellular signal-
regulated kinases (ERKs), the p38 MAPKs, and the c-Jun 
N-terminal kinases (JNKs) [11]. Generally, ERK cascades 
are often activated by growth factors and survival factors 
that are associated with cell survival. In contrast, the JNK 
and p38 MAPK pathways are activated by stress stimuli 
that are frequently associated with pro-apoptotic effects 
[3, 12]. Interestingly, diverse apoptotic stimuli such 
as ROS and tumor necrosis factor TNF-α can induce 
apoptosis signal-regulated kinase (ASK)1 activation, 
eventually resulting to the activation of JNK signalling 
cascade and apoptosis [13, 14]. Numerous studies have 
described that JNK activation may initiate apoptotic 
signalling via two different strategies. The first strategy 
is to directly activate mitochondrial pro- and anti-
apoptotic proteins such as Bcl-2 proteins [15], whereas 
as another indirect strategy can be mediated via the 
rapid translocation of the JNK to the nucleus where it 
phosphorylates and regulates the activity of transcription 
factors such as c-Jun, which further upregulates pro-
apoptotic genes [16, 17].
Benzimidazoles are heterocyclic aromatic 
compounds that contained a fusion of a phenyl and 
imidazole ring [18]. Benzimidazoles and their derivatives 
possess many important pharmacological properties; for 
example omeprazole (proton pump inhibitor), pimobendan 
(ionodilator), and mebendazole (anthelmintic) [19, 20]. 
Benzimidazole-derived scaffolds are gaining attention 
in medicinal chemistry because of the presence of a 
heterocyclic imidazole ring that provides excellent 
possibilities for generating potential anti-cancer agents 
[21]. In search of novel anti-cancer drugs, we synthesized 
a series of benzimidazole derivatives and screened 
them against a panel of human cancer cell-lines. One 
promising hit, Methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- 
benzo[d]imidazole-5-carboxylate (MBIC) (Figure 1A), 
showed potent anti-proliferative activity compared to 
the chemotherapeutic drug cisplatin [22]. In the present 
study, the possible molecular mechanism(s) underlying 
the anticancer effects of MBIC were investigated in 
diverse HCC cell lines. It was observed that MBIC-
induced apoptosis might be mediated by the ROS-induced 
activation of JNK signaling in HCC cells that led to the 
inhibition of tumor growth in an orthotopic mouse model.
RESULTS
MBIC inhibits viability and induces substantial 
apoptosis in diverse HCC cell lines
The effect of MBIC on cellular viability was 
analyzed by MTT assay in various HCC cells. As shown 
in Figure 1B, MBIC was highly cytotoxic towards 
HepG2, Hep3B, Huh7, SNU387, and SK-Hep-1 cells, 
with IC50 values of 0.39, 1.20, 0.32, 0.69, and 1.30 μg/mL 
respectively at 72 h. Comparatively, HCCLM3, a highly 
metastatic cell line, was more resistant to MBIC treatment 
as compared to other HCC cells [23], and its IC50 value 
was around 15.18 μg/mL. A parallel study was performed 
to determine the effect of MBIC against normal liver cells. 
No significant inhibition was found in normal liver cell 
line, LO2 cells after treatment with MBIC for 72 h, and 
the IC50 value was found to be higher than 40 µg/mL. 
The apoptotic potential of MBIC was measured by 
flow cytometry after staining with PI. After treatment for 
72 h, induction of apoptosis in both HepG2 and Huh7 was 
dramatically increased with increasing concentrations of 
MBIC from 0.1 to 0.8 μg/mL (Figure 1C), which was 
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consistent with the MTT results. The percentage of SubG1 
cells in the normal LO2 hepatic cell line was always less 
than 10% at the different concentrations of MBIC for 
72 h. Next, PI-Annexin V double staining was used to 
further identify the effects of MBIC on cellular apoptosis. 
Interestingly, PI-Annexin V double positive population, 
which indicates the later stage of apoptosis, also increased 
in a dose-dependent manner after treatment with MBIC 
for 72 h in both HepG2 and Huh7 cells (Figure 1D). These 
results suggest that MBIC can significantly inhibit the 
growth of HCC cells and induce substantial apoptosis in 
a dose-dependent manner, while being significantly less 
cytotoxic towards normal liver cells.
MBIC-induces apoptosis through caspase-
mediated pathway
It has been reported that mitochondria and 
caspases are the central executioners of apoptosis [24]. 
To investigate the contribution of mitochondria in 
MBIC-induced apoptosis of HCC cells, the mitochondrial 
membrane potential (Δψm) was measured by staining 
cell with TMRE. As shown in Figure 2A, the Δψm 
was significantly decreased after exposure to 0.4 and 
0.8 μg/mL of MBIC for 12 h. Next, we investigated 
the protein levels of various pro-apoptotic proteins by 
Western blot analysis. The results shown in Figure 2B 
Figure 1: The effect of MBIC on suppression of cell viability and the induction of apoptosis in HCC cells. (A) The chemical 
structure of MBIC. (B) MTT assay was performed to determine IC50 values upon exposure to different concentrations of MBIC for 72 h. 
(C) SubG1 percentage was determined by Propidium Iodide staining. Cells were treated with MBIC at 0.1, 0.2. 0.4 or 0.8 μg/ml for 72 h. 
After staining with Propidium Iodide, the cells were analyzed using a flow cytometer. Error bars are means ± SD. Ordinary one-way 
ANOVA with Dunnett’s Multiple Comparison Test (**p < 0.01). (D) The Annexin V and PI apoptosis assay demonstrating the increase in 
Annexin V-PI positive cell populations with increasing dose of MBIC. 
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indicate that protein levels of Bcl-2 and XIAP were 
decreased and cytochrome c level was increased in 
HepG2 and Huh7 cells after treatment with the MBIC 
for 24 h. In addition, the expression of active form, tBid, 
was triggered in a dose-dependent manner in MBIC-
treated Huh7 cells although full length Bid level was 
found to be increased for unclear reasons that require 
further analysis. To determine the contribution of 
caspases to the apoptotic process, the level of caspase 
family proteins was assessed by Western blotting 
analysis. As shown in Figure 2C, MBIC induced the 
cleavage of caspase-8 and caspase-3 in a dose-dependent 
manner in HCC cells. Taken together, the data suggest 
that MBIC-induced apoptosis might be mediated by 
caspase-dependent process.
MBIC inhibits cellular migration and invasion in 
HCC cells
We next examined whether MBIC could also affect 
the migratory and invasive behavior of HCC cells. The 
chamber invasion assay was performed to investigate 
cellular invasive ability. As shown in Figure 3A, the results 
indicated that MBIC significantly reduced the infiltration 
rates of HepG2 and Huh7 cells compared to the untreated 
control cells at two different concentrations. Meanwhile, 
Figure 2: The potential effect of MBIC on the cellular apoptotic pathways. (A) The mitochondrial potential level was 
determined by staining with TMRE. Huh 7 cells were treated with various concentrations of MBIC for 24 h and then stained by 1 μΜ 
TMRE. 10 μM FCCP was added as a positive control.  Error bars are means ± SD n = 2. Ordinary one-way ANOVA with Dunnett’s Multiple 
Comparison Test (*p < 0.05; **p < 0.01). (B) The expression of various proteins was determined by Western blot analysis after treatment 
with indicated concentrations of MBIC for 24 h. (C) Caspase family proteins were analysed by Western blotting. 
Oncotarget12835www.impactjournals.com/oncotarget
the effect of MBIC on Huh7 cells was found to be more 
effective than HepG2 at the 0.4 µg/ml. In addition, the 
scratch wound healing assay also demonstrated similar 
results for HepG2 and Huh7 cells, indicating that MBIC 
could significantly reduce the migration of both HCC cell 
lines (Figure 3B). These results cumulatively suggest that 
MBIC could exert an inhibitory effect on both cellular 
migration and invasion of HCC cells.
MBIC activates ROS-dependent JNK signaling 
pathway 
Numerous studies have demonstrated that ROS 
production can significantly induce apoptosis [25]. To 
investigate whether ROS generation is one of the upstream 
molecular events involved in MBIC-induced apoptosis, we 
used flow cytometry analysis to examine ROS generation 
with the fluorescent probe 2,7-dichlorodihydrofluorescein 
diacetate (DCFH2-DA). As shown in Figure 4A, the 
rapid generation of ROS was detected at 2 h following 
MBIC treatment. Compared with the control, about 8-fold 
change was found after exposure to 0.8 µg/mL MBIC for 
2 h. Previous reports also have indicated that N-acetyl 
cysteine (NAC), a ROS scavenger, can prevent apoptosis 
and promote cell survival [26, 27]. Interestingly, it was 
noted that the effect of MBIC on ROS production was 
partially reversed by pre-treatment with 5 mM NAC for 
2 h (Figure 4B). Furthermore, as shown in Figure 4C, 
Figure 3: MBIC abrogates cellular migration and invasion. (A) HepG2 and Huh7 cells were either untreated or treated with 
MBIC for 12 h and subjected to the invasion (with Matrigel) assays. Invasive cells were imaged by bright-field microscope under × 100 
magnification. Representative images are shown for indicated concentrations of MBIC, and results were quantified using Image J software. 
(B) Scratch wound-healing assay performed in HepG2 and Huh7 cells with or without MBIC treatment. Results are also quantified using 
Image J software. (Magnification × 100). Error bars are means ± SD. Ordinary one-way ANOVA with Dunnett’s Multiple Comparison Test 
(*p < 0.05; **p < 0.01). 
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NAC also partially abolished the MBIC-induced cleaved-
caspase-3 expression, which plays a central role in the 
execution-phase of apoptosis. 
It has been reported that ROS could induce the 
phosphorylation and sustained activation of MAPK 
signaling proteins such as ERK, p38, and JNK [28]. 
In order to investigate whether MBIC-induced ROS 
production leads to the activation of MAPK signaling 
proteins, we employed Western blot analysis to examine 
the effect of MBIC on phosphorylation status of these 
proteins. As shown in Figure 4D, no obvious change 
of phospho-ERK and a slight increase in phospho-p38 
MAPK were observed upon MBIC treatment in HCC 
cells. However, the expression of p-JNK was substantially 
up-regulated in a dose-dependent manner after MBIC 
treatment. To further investigate the mechanisms 
underlying ROS-dependent JNK activation, we determined 
the effect of NAC on the JNK phosphorylation that can be 
induced upon MBIC treatment. As shown in Figure 4E, 
Western blotting results showed that the MBIC-induced 
JNK activation could also be abrogated by NAC in a dose-
dependent manner. Altogether, all these results indicated 
that MBIC-induced apoptosis might be mediated through 
a ROS-dependent JNK signaling pathway. 
MBIC did not produce any significant toxic 
effects in mice
We next carried out acute toxicity studies with MBIC 
to determine its sub-lethal dose for in vivo studies. The 
mice were monitored for 8 days after the intraperitoneal 
administration of the 10, 25, or 50 mg/kg dose of MBIC 
and vehicle (0.1% DMSO). At the end of the experiment, no 
mortality was observed, which indicated that the LD50 must 
be higher than 50 mg/kg. As shown in the Figure 5A–5C, 
there was no significant difference of behavioral and physical 
symptoms such as body weight, feed consumption, and water 
intake between MBIC treated groups and the control group. 
The various biochemical parameters of the serum 
including alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), and blood urea nitrogen (BUN) 
were detected by the autoanalyzer. It was observed that 
Figure 4: MBIC activates JNK signaling pathway via ROS generation. (A) The quantity of ROS were analysed by H2DCF-
DA staining after treatment with MBIC for 2 h. (B) Huh7 cells were exposed to 0.4 μg/mL MBIC with or without NAC (5 mM) for 2 h, 
and then ROS production was analyzed by staining with H2DCF-DA. (C) Huh7 cells were exposed to 0.4 μg/mL MBIC with or without 
NAC (5 mM) for 24 h. The expression of cleaved-caspase-3 was determined by Western blotting analysis. (D) Huh7 cells were treated with 
various concentrations of MBIC for 8 h. The ERK, P38, and JNK phosphorylation was determined by Western blotting analysis. (E) Huh7 
cells were exposed to 0.4 μg/mL MBIC with or without the indicated concentrations of NAC for 2 h. The activation of JNK was determined 
by Western blotting analysis. 
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compared to the control group, no substantial differences 
were found in the serum levels of ALT, AST, and BUN in 
the MBIC-treated groups. All these results indicate that the 
intraperitoneal administration of MBIC did not produce 
any obvious toxic effects in NCr nude mice (Figure 5D). 
MBIC inhibited tumor growth in an orthotopic 
HCC mouse model
We also analyzed the anti-tumor potential of 
MBIC in vivo via intraperitoneal administration using 
the Huh7_Luc orthotopic model. After treatment with 
25 mg/kg of MBIC (three doses per week for 4 consecutive 
weeks), bioluminescence images revealed that there was a 
significant reduction of tumor growth in the MBIC group 
compared with the vehicle control group at the end of the 
assay (Figure 6A). The differences in tumor burden at the 
last point was quantitated by measuring photon counts and 
expressed as the tumor burden relative to photon counts 
before the first therapeutic injection. An unpaired t test 
with Welch’s correction indicated that the MBIC treatment 
group had significant inhibition of tumor burden compared 
with the vehicle-treated controls (Figure 6B).
We further evaluated the effect of MBIC on 
the expression level of p-JNK in tumor tissues by 
immunohistochemistry and found that MBIC substantially 
increased JNK phosphorylation in drug treated group 
as compared with the control group. Consistently, the 
expression of cleaved-caspase-3 staining in HCC tumor 
tissues was also increased after MBIC treatment, especially 
in cells present in the close vicinity to the blood vessels. 
Moreover, the expression of proliferative biomarker, Ki67 
was down-regulated in treated group as compared to the 
control group (Figure 6C). The protein levels of p-JNK, 
cleaved-caspase-3, and cleaved-caspase-8 in tumor tissues 
were further investigated by Western blotting analysis, and 
the results also showed a marked increase in expression of 
these proteins in the MBIC treatment group (Figure 6D). 
Overall, these results indicate that MBIC exerts its anticancer 
effects by modulating the expression of diverse biomarkers 
associated with tumor growth and survival.
DISCUSSION
We had previously prepared various substituted 
2-(phenyl)-3H-Benzo[d]Imidazole-5-carboxylic acids and 
their methyl esters and then screened them for their anti-
proliferative effects against breast cancer cell lines [22]. 
Although benzo [d]imidazole-5-carboxylic acids showed 
only modest effect, the compound MBIC with 2-hydroxyl 
and 5-fluoro substitution in the aryl ring was found to 
exert the most potent anti-proliferative effects against 
breast cancer cells. In this study, we performed MTT assay 
to demonstrate that MBIC could significantly inhibit cell 
viability in a panel of HCC cells, especially in HepG2 
and Huh7 cells, with IC50 values of 0.39 and 0.32 μg/mL 
respectively. Interestingly, no obvious cytotoxic effect 
of the drug was observed on normal liver cells in which 
the IC50 was found to be higher than 40 μg/mL. These 
results suggested that MBIC specifically inhibited growth 
potential of liver cancer cells, but had no detrimental effect 
on normal liver cells. 
Figure 5: Acute toxicity studies with MBIC. (A) The effect of intraperitoneal administration of MBIC on body weight change. The 
nude mice were treated with one single dose of MBIC (10, 25, or 50 mg/kg). Error bars are means ± SD. Ordinary one-way ANOVA with 
Dunnett’s Multiple Comparison Test. (B–C) The effect of MBIC on mice behavior study including feed consumption (B) and water intake 
(C). Error bars are means ± SD. Ordinary one-way ANOVA with Dunnett’s Multiple Comparison Test. (D) Effect of MBIC on biochemical 
parameters. 
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The induction of cellular apoptosis constitutes the 
main strategy for cancer treatment [29]. Here, we used 
an Annexin V-PI staining assay to reveal that MBIC 
induced apoptosis of HCC cells. To examine the molecular 
mechanism(s) underlying this MBIC-induced apoptosis, 
we analyzed the changes of mitochondrial membrane 
potential, which is an important step in initiating intrinsic 
apoptotic pathway [30]. Our results indicated that MBIC 
significantly decreased mitochondrial membrane potential 
in HCC cells. The loss of the mitochondrial membrane 
potential mediated by proteins from the Bcl-2 family, 
could lead to the release of apoptogenic factors such as 
cytochrome c into the cytoplasm. This in turn trigger 
activation of caspase-9 and caspase-3, which play a 
pivotal role in the execution of apoptosis [31]. The down-
regulation of anti-apoptotic Bcl-2 and up-regulation of 
pro-apoptotic Bid proteins was found after treatment 
with MBIC for 24 h. Meanwhile, MBIC also increased 
cytochrome c and cleaved-caspase-3 expression. These 
results suggest that the intrinsic apoptotic pathway may be 
predominantly involved in the MBIC-induced apoptosis. 
The extrinsic apoptotic pathway can be activated by cell 
surface death receptors, such as TNF-related apoptosis-
inducing ligand (TRAIL), leading to the activation 
of caspase-8 [32]. An apparent induction of cleaved 
caspase-8 was also detected, indicating that MBIC-
induced apoptosis may also involve extrinsic pathway to 
some extent in HCC cells. However, the exact roles of 
both intrinsic and extrinsic pathways in MBIC-induced 
apopotosis requires additional detailed investigations.
Figure 6: MBIC significantly inhibits tumor growth in an orthotopic mouse model. (A) Bioluminescence images of 
orthotopically implanted tumours. Ncr nude mice were orthotopically implanted with Huh 7_Luc cell-induced tumors and then treated with 
0.1% DMSO (n = 9) or 25 mg/kg MBIC (n = 10) for 29 days. (B) The scatter plot represents the differences in tumor burden at the last 
point by measuring photon counts and is expressed as tumor burden relative to photon counts before first therapeutic injection. Unpaired 
t test with Welch’s correction (**p < 0.01). (C) Immunohistochemistry showing p-JNK, cleaved-caspase-3, and Ki 67 levels in tumors from 
vehicle control or 25 mg/kg MBIC-treated mice. Fold change of positive staining for the biomarkers was shown. Magnification 200 ×. 
(D) The western blot analysis of p-JNK and caspase family proteins in tumor tissues. At least three samples were analyzed from each group. 
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An excessive ROS production leads to disruption of 
intracellular redox homeostasis, which can induce cellular 
apoptosis through the both intrinsic and extrinsic pathways 
[33]. It is well documented that excessive production of 
ROS may activate MAPK signalling cascades such as 
JNK pathway, which plays an important role in many 
cellular events [16]. A recent report has identified that 
another new benzimidazole acridine derivative, N-{(1H-
benzo[d]imidazol-2-yl)methyl}-2-butylacridin-9-amine, 
can induce apoptosis via the ROS-JNK signaling pathway 
in human colorectal cancer cell lines [34]. Consistent with 
this study, MBIC was also found to induce a substantial 
increase of ROS production and JNK phosphorylation in 
HCC cells. This ROS production was found to be partially 
abrogated upon NAC treatment. Because oxidative stress 
can be controlled by different antioxidant mechanisms 
such as antioxidant modulators and enzymatic scavengers 
[35], our results suggest that diverse mechanism(s) may 
be involved in MBIC-induced ROS production. Taken 
together, our findings suggest that the ROS-JNK pathway 
may be involved in MBIC-induced apoptosis. The exact 
apoptosis relationship between MBIC-mediated ROS 
production, apoptosis and activation of JNK signal 
transduction requires further investigation.
In conclusion, our study is the first to demonstrate 
that MBIC can induce substantial apoptosis mediated 
by the ROS/JNK signalling pathway and significantly 
abrogate tumor growth in an orthotopic mouse model 
without exhibiting any major adverse effects. The 
findings of this study expand the potential understanding 
of molecular mechanisms(s) mediating anticancer effects of 




The detailed protocol for the synthesis of MBIC 
was well-described in a previous published paper [22]. 
The chemical structure of the synthesized compound 
was confirmed using different spectroscopic techniques, 
including 1H NMR, IR, and LC–MS analyses and 
elemental analysis.
Cell lines
HepG2, Hep3B, SNU387, SK-Hep-1, and LO2 
cell lines were obtained from American Type Culture 
Collection. Huh7 and HCCLM3 cell lines were a kind 
gift from Professor Zhao-You Tang at the Liver Cancer 
Institute (Zhongshan Hospital, Fudan University, 
Shanghai). All the HCC cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) with 10% FBS. 
MTT assay
HCC cells (4~7 × 103) were seeded in 96-well 
plates, and then treated with indicated concentrations of 
MBIC for 72 h. After treatment, the cells were incubated 
with 20 μL 5 mg/mL MTT for 2 to 4 hours until a purple 
precipitate was visible. Thereafter, 0.1 mL lysis buffer 
(20% SDS, 50% dimethylformamide) was added after 
removal of the medium, and then incubated at 37°C for 
1 h. The absorbance was measured at 570 nm using a 
Tecan plate reader.
Wound healing assay
An Ibidi Culture–Insert (Ibidi GmbH, Germany) 
was used for the scratch wound healing assays. HCC 
cells (7 × 105) were seeded in the Culture-Insert to form 
a confluent layer within 24 hours, and then treated with 
different concentrations of MBIC for 8 h. A cell-free gap 
of 500 μm was created after gently removing the Culture-
Insert. The wounds were observed using microscopy 
(Olympus DP 70, Japan) after migration for 24 h and the 
gap closure was measured. 
Invasion assay
HCC cells were seeded in a Bio-Coat Matrigel 
invasion chamber (BD, USA) with FBS-free medium 
overnight. After incubation with MBIC for 8 h, the 
medium was changed to DMEM medium with 10% FBS. 
After invasion for 24 h, the inserts were stained by the 1% 
crystal violet and observed using bright field microscopy 
(Olympus DP 70, Japan). 
PI staining
Treated cells were harvested by trypsin without 
EDTA, washed by PBS, and fixed with 70% ethanol for 
30 mins. The cells were stained with propidium iodide 
solution, and intensity of fluorescence was measured by 
flow cytometry (BD, Biosciences, San Jose, CA) using the 
FL2-PI channels.
Annexin V-PI staining
Apoptosis was assessed by Annexin V-PI staining 
(Santa cruz Co, CA). After treatment, the cells were 
harvested by trypsin without EDTA, and washed using 
ice-cold PBS. The cells were suspended in 1 × Annexin V 
binding buffer and incubated with 1 μL Annexin V-FITC 
conjugate and 12.5 μL propidium iodide (PI) solution 
(Santa cruz) for 15 mins. The intensity of the fluorescence 
was immediately detected using FL1-FITC (Annexin V) 
and FL2-PI Channels.
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Measurement of ROS production
Huh7 Cells (5 × 105) were seeded in 6-well plates 
overnight and then treated with MBIC in the absence or 
presence of N-Acetyl cysteine (NAC) for the indicated 
times. After treatment, the cells were harvested and stained 
with 10 µM 2′,7′-Dichlorofluorescin diacetate (DCFH-
DA) at 37°C for 30 min in the dark. The fluorescence was 
measured by flow cytometry (BD, Biosciences, San Jose, 
CA) using FITC channel. 
Estimation of mitochondrial membrane potential 
(Δψm)
The change mitochondrial membrane potential was 
tested using Abcam’s TMRE Mitochondrial Membrane 
Potential Assay Kit (ab113852). The Huh7 cells 
(7 × 103) were seeded in 96-well plates overnight. Then 
the cells were incubated with indicated concentrations 
of MBIC for 12 h. 20 μM FCCP (carbonyl cyaninde 
4-(trifluoromethoxy) phenylhydrazone), the positive 
control, was added to the cell medium 10 mins before 
staining. 1 μM Tetramethylrhodamine, ethyl ester (TMRE) 
was added to the cells and incubated for 20 mins 37ºC. 
The TMRE staining was analyzed using a by microplate 
spectrophotometer (Tecan) at Ex/Em = 549/575 nm.
Western blotting
Whole-cell extracts were lysed in pre-cold lysis 
buffer with freshly added protease/phosphatase inhibitors. 
After 30 mins, the lysates were then spun at 13,300 rpm 
for 10 minutes and the pellet was discarded. Equal amount 
of protein were loaded for electrophoresis and then electro-
transferred to a nitrocellulose membrane (Biorad, USA), 
which was blocked with Blocking One (Nacalai Tesque, 
Inc., Japan), and probed with the primary antibodies of 
interest overnight at 4°C. The blot was washed, exposed 
to HRP-conjugated secondary antibodies (Santa Cruz Co, 
CA) for 1 h, and finally examined by chemiluminescence 
(ECL, advansta Inc., USA). 
Acute toxicity studies
All animal experiments were performed according 
to protocols approved by the SingHealth Institutional 
Animal Use and Care Committee. For the acute toxicity 
drug study, eight week-old NCr nude female mice 
(In vivos, Singapore) were treated with intraperitoneal 
injections of 10 mg/kg, 25 mg/kg, or 50 mg/kg of MBIC, 
and vehicle (0.1% DMSO). The mice were monitored 
daily for development of any toxic signs such as change in 
physical appearance, hunched back, increased respiration, 
arching and rolling, muscle spasm, tremors, cyanosis, 
stimulation or depression. The body weight changes, food 
and water intake were monitored daily up to day 8. On 
day 8, the terminal blood from the mice was collected by 
cardiac puncture. The liver and kidney functions were 
studied using the serum. Three main criteria {Alanine 
transaminase (ALT), Aspartate transaminase (AST)} were 
examined for liver function, and Blood urea nitrogen 
(BUN) for kidney function.
Orthotopic HCC tumor model 
For the drug efficacy study, eight week-old NCr nude 
females were implanted orthotopically with Huh-7-Luc cell-
induced tumors. When the bioluminescence signal reached 
106, mice were treated with either vehicle (1% DMSO) or 
25 mg/kg of MBIC three times per week by intraperitoneal 
injections for 4 consecutive weeks. The development of 
the tumor was monitored twice a week by measuring the 
bioluminescence signals. Mice were euthanized by using 
CO2 inhalation when the humane end-point criteria were 
met. Primary tumor (liver) and lung tissues were excised, 
snap-frozen, and stored at –80°C until used for experiments.
Immunohistochemistry
The control and MBIC-treated mice tissues were 
fixed with 4% formaldehyde and then dehydrated in 
graded ethanols and xylene. After embedding with 
paraffin, the tissue was sliced into 5 μm sections and 
the slides were baked at 60°C for 2 h. The antigens of 
the deparaffinised sections were unmasked by boiling in 
10 mM sodium citrate buffer (pH 6.0), and microwaved 
four times for 6 mins each time. After the sections cooled 
down to room temperature, they were incubated with 
3% H2O2 for 10 mins and blocked by using blocking one 
(Nacalai Tesque, Inc.) for 1 h. Next, the sections were 
incubated with the primary antibodies p-JNK (1:50), Ki67 
(1:100) and cleaved-caspase3 (1:100) at 4°C overnight. 
After washing, the slides were incubated with EnVision 
polymer HRP-Rabbit (DAKO) for 1 h and visualized 
by using 3, 3′-diamino-benzidine (DAB). Sections were 
counterstained using Hematoxylin, and cover-slipped after 
using a mounting medium (Sigma). Images were taken 
using an Olympus BX51 microscope.
Statistical analysis
The Student’s t test or one way ANOVA with 
Dunnett’s Multiple Comparison Test was used for the 
comparison of measurable variants. All data are presented 
as means and standard errors of the mean. p < 0.05 was 
considered statistically significant (GraphPad Prism 5.0; 
Graph Pad Software, CA). The migration and invasion 
data was quantified by using Image J software.
ACKNOWLEDGMENTS AND FUNDING
This work was supported by NUHS Basic seed grant 
[T1-BSRG 2015-02] and Ministry of Education Tier 1 grant 
to GS. GS was also supported by the John Nott Cancer 
Oncotarget12841www.impactjournals.com/oncotarget
Fellowship from Cancer Council, Western Australia. APK 
was supported by grants from National Medical Research 
Council of Singapore, NCIS Yong Siew Yoon Research 
Grant through donations from the Yong Loo Lin Trust 
and by the National Research Foundation Singapore and 
the Singapore Ministry of Education under its Research 
Centers of Excellence initiative to Cancer Science Institute 
of Singapore, National University of Singapore.  This work 
was supported by National Medical Research Council of 
Singapore grant to KMH. This study was also supported 
by University Malaya High Impact research grant [HIR 
Project number: UM.C/HIR/MOHE/MED/03; HIR account 
number: UM.0000062/HIR.C1 (H-20001-E000002)], 
UMRG (RP027A-14HTM). The authors extend their 
appreciation to the International Scientific Partnership 
Program ISPP at King Saud university for funding their 




1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, 
Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 
2015; 65:87–108.
2. Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, 
Marrero JA, Lok AS, Lee WM. Detection of hepatocellular 
carcinoma at advanced stages among patients in the 
HALT-C trial: where did surveillance fail? Am J 
Gastroenterol. 2013; 108:425–432.
3. Lencioni R, Chen XP, Dagher L, Venook AP. Treatment 
of intermediate/advanced hepatocellular carcinoma in the 
clinic: how can outcomes be improved? Oncologist. 2010; 
15:42–52.
4. Zhu AX. Systemic therapy of advanced hepatocellular 
carcinoma: how hopeful should we be? Oncologist. 2006; 
11:790–800.
5. Yoon KT, Choi JW, Park JY, Ahn SH, Paik YH, Lee KS, 
Han KH, Chon CY, Kim DY. Clinical outcomes of systemic 
chemotherapy in hepatocellular carcinoma patients with 
multiple lung metastases. Korean J Hepatol. 2008; 14:360–370.
6. Renschler MF. The emerging role of reactive oxygen species 
in cancer therapy. Eur J Cancer. 2004; 40:1934–1940.
7. Toler SM, Noe D, Sharma A. Selective enhancement of 
cellular oxidative stress by chloroquine: implications for 
the treatment of glioblastoma multiforme. Neurosurg Focus. 
2006; 21:E10.
8. Scandalios JG. Oxidative stress: molecular perception and 
transduction of signals triggering antioxidant gene defenses. 
Braz J Med Biol Res. 2005; 38:995–1014.
9. Son Y, Cheong YK, Kim NH, Chung HT, Kang DG, 
Pae HO. Mitogen-Activated Protein Kinases and Reactive 
Oxygen Species: How Can ROS Activate MAPK Pathways? 
J Signal Transduct. 2011; 2011:792639.
10. Plotnikov A, Zehorai E, Procaccia S, Seger R. The 
MAPK cascades: signaling components, nuclear roles and 
mechanisms of nuclear translocation. Biochim Biophys 
Acta. 2011; 1813:1619–1633.
11. Johnson GL, Lapadat R. Mitogen-activated protein kinase 
pathways mediated by ERK, JNK, and p38 protein kinases. 
Science. 2002; 298:1911–1912.
12. Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth 
factors and receptor tyrosine kinases. Biochim Biophys 
Acta. 2007; 1773:1161–1176.
13. Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, 
Morita K, Takeda K, Minowa O, Miyazono K, Noda T, 
Ichijo H. ASK1 is required for sustained activations of 
JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2001; 
2:222–228.
14. Takeda K, Noguchi T, Naguro I, Ichijo H. Apoptosis signal-
regulating kinase 1 in stress and immune response. Annu 
Rev Pharmacol Toxicol. 2008; 48:199–225.
15. Wu CC, Bratton SB. Regulation of the intrinsic apoptosis 
pathway by reactive oxygen species. Antioxid Redox 
Signal. 2013; 19:546–558.
16. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. 
Oncogene. 2008; 27:6245–6251.
17. Chang L, Karin M. Mammalian MAP kinase signalling 
cascades. Nature. 2001; 410:37–40.
18. Wright JB. The chemistry of the benzimidazoles. Chem 
Rev. 1951; 48:397–541.
19. C Torres F, Eugenia Garcia-Rubino M, Lozano-Lopez C, 
F Kawano D, L Eifler-Lima V, L von Poser G, M Campos 
J. Imidazoles and Benzimidazoles as Tubulin-Modulators 
for Anti-Cancer Therapy. Current Med Chem. 2015; 22: 
1312–1323.
20. Hasanpourghadi M, Karthikeyan C, Pandurangan AK, 
Looi CY, Trivedi P, Kobayashi K, Tanaka K, Wong WF, 
Mustafa MR. Targeting of tubulin polymerization and 
induction of mitotic blockage by Methyl 2-(5-fluoro-2-
hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate (MBIC) 
in human cervical cancer HeLa cell. J Exp Clin Cancer Res. 
2016; 35:58.
21. Yadav G, Ganguly S. Structure activity relationship (SAR) 
study of benzimidazole scaffold for different biological 
activities: A mini-review. Eur J Med Chem. 2015; 97: 
419–443.
22. Karthikeyan C, Solomon VR, Lee H, Trivedi P. Synthesis 
and biological evaluation of 2-(phenyl)-3H-benzo [d] 
imidazole-5-carboxylic acids and its methyl esters as potent 
anti-breast cancer agents. Arabian J Chem. 2013.
23. Yang J, Qin LX, Li Y, Ye SL, Liu YK, Gao DM, Chen J, 
Tang ZY. Molecular cytogenetic characteristics of the 
human hepatocellular carcinoma cell line HCCLM3 
with high metastatic potential: comparative genomic 
Oncotarget12842www.impactjournals.com/oncotarget
hybridization and multiplex fluorescence in situ 
hybridization. Cancer Genet Cytogenet. 2005; 158: 
180–183.
24. Green D, Kroemer G. The central executioners of apoptosis: 
caspases or mitochondria? Trends Cell Biol. 1998; 8:267–
271.
25. Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive 
oxygen species (ROS) in apoptosis induction. Apoptosis. 
2000; 5:415–418.
26. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular 
mechanisms of N-acetylcysteine actions. Cell Mol Life Sci. 
2003; 60:6–20.
27. Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry 
and biological activities of N-acetylcysteine. Biochim 
Biophys Acta. 2013; 1830:4117–4129.
28. McCubrey JA, Lahair MM, Franklin RA. Reactive oxygen 
species-induced activation of the MAP kinase signaling 
pathways. Antioxid Redox Signal. 2006; 8:1775–1789.
29. Ferreira CG, Epping M, Kruyt FA, Giaccone G. Apoptosis 
target of cancer therapy. Clin Cancer Res. 2002; 8: 
2024–2034.
30. Kroemer G, Galluzzi L, Brenner C. Mitochondrial 
membrane permeabilization in cell death. Physiol Rev. 
2007; 87:99–163.
31. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis 
pathways in anticancer chemotherapy. Oncogene. 2006; 
25:4798–4811.
32. Wilson MR. Apoptotic signal transduction: emerging 
pathways. Biochem Cell Biol. 1998; 76:573–582.
33. Circu ML, Aw TY. Reactive oxygen species, cellular 
redox systems, and apoptosis. Free Radic Biol Med. 2010; 
48:749–762.
34. Chen K, Chu BZ, Liu F, Li B, Gao CM, Li LL, Sun QS, 
Shen ZF, Jiang YY. New benzimidazole acridine derivative 
induces human colon cancer cell apoptosis in vitro via the 
ROS-JNK signaling pathway. Acta Pharmacol Sin. 2015; 
36:1074–1084.
35. Kalyanaraman B, Darley-Usmar V, Davies KJ, Dennery PA, 
Forman HJ, Grisham MB, Mann GE, Moore K, Robert LJ, 
Ishiropoulos H. Measuring reactive oxygen and nitrogen 
species with fluorescent probes: challenges and limitations. 
Free Radic Biol Med. 2012; 52:1–6.
